logo

Amarin Corp Plc (AMRN)



Trade AMRN now with
  Date
  Headline
9/24/2018 4:53:02 AM Amarin Says REDUCE-IT Study Met Its Primary Endpoint
8/26/2018 11:06:31 AM Amarin Says REDUCE-IT Study Remains On-Track For Report Of Top-Line Results Before End Of September 2018
8/1/2018 5:03:44 AM Amarin Corp Q2 Loss Per Share $0.12 Vs Loss $0.05 Last Year
7/26/2018 8:51:35 AM Amarin Reports Approval For Vascepa In UAE
5/24/2018 4:35:38 PM Amarin Announces Patent Litigation Settlement Agreement With Teva
5/2/2018 5:04:33 AM Amarin Corp Q1 Net Loss $24.1 Mln Or $0.08/Shr Vs Loss $20.9 Mln Or $0.08/Shr Last Year
4/23/2018 5:01:17 AM Amarin Announces Promotion Of Aaron Berg To Chief Commercial Officer
4/12/2018 5:02:26 AM Amarin Corp: Vascepa Showed Reductions In Potentially Atherogenic Lipid And Inflammatory Markers
4/6/2018 8:49:30 AM Jefferies Is Cutting Amarin Corp Plc (AMRN) 2020 Estimate To -0.01 From 0.03
4/6/2018 8:49:05 AM Jefferies Is Lowering Amarin Corp Plc (AMRN) 2019 Estimate To -0.33 From -0.05
4/6/2018 8:48:45 AM Jefferies Is Cutting Amarin Corp Plc (AMRN) 2018 Estimate To -0.33 From -0.32
4/4/2018 5:29:03 AM Amarin Estimates Q1 Net Product Revenue Likely To Be About $43 Mln
4/4/2018 5:07:02 AM Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark For Estimated Onset Of Targetet MACE
  
 
>